OncoSec Medical (ONCS) Given Daily Coverage Optimism Rating of 0.16

Media coverage about OncoSec Medical (NASDAQ:ONCS) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoSec Medical earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.6976076482839 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of OncoSec Medical stock traded up $0.06 during mid-day trading on Friday, reaching $1.77. The company’s stock had a trading volume of 3,617,924 shares, compared to its average volume of 885,468. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Friday, March 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). equities research analysts predict that OncoSec Medical will post -0.86 EPS for the current year.

A number of equities analysts have commented on the company. HC Wainwright set a $6.00 target price on OncoSec Medical and gave the company a “buy” rating in a research note on Friday, January 19th. ValuEngine downgraded OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Maxim Group set a $5.00 target price on OncoSec Medical and gave the company a “buy” rating in a research note on Thursday, March 15th. Finally, Piper Jaffray Companies assumed coverage on OncoSec Medical in a research note on Friday, February 9th. They issued an “overweight” rating and a $4.00 target price for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. OncoSec Medical presently has a consensus rating of “Buy” and a consensus price target of $5.00.

In other OncoSec Medical news, CEO Daniel J. O’connor acquired 16,667 shares of OncoSec Medical stock in a transaction dated Monday, February 5th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the completion of the transaction, the chief executive officer now owns 16,667 shares in the company, valued at approximately $25,000.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “OncoSec Medical (ONCS) Given Daily Coverage Optimism Rating of 0.16” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299573/oncosec-medical-oncs-given-daily-coverage-optimism-rating-of-0-16.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Novavax  Price Target Cut to $2.00
Novavax Price Target Cut to $2.00
Scorpio Tankers  Forecasted to Post Q1 2018 Earnings of  Per Share
Scorpio Tankers Forecasted to Post Q1 2018 Earnings of Per Share
PC Tel  Stock Rating Upgraded by Zacks Investment Research
PC Tel Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research Downgrades REGENXBIO  to Sell
Zacks Investment Research Downgrades REGENXBIO to Sell
HC Wainwright Reiterates “Buy” Rating for Synlogic
HC Wainwright Reiterates “Buy” Rating for Synlogic


© 2006-2018 Ticker Report. Google+.